TSXV:BRM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BIOREM Inc., an environmental biotechnology company, designs, manufactures, and sells air emissions control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). More Details


Snowflake Analysis

Flawless balance sheet and fair value.

Share Price & News

How has BIOREM's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BRM has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

BRM

-1.6%

CA Commercial Services

-1.0%

CA Market


1 Year Return

5.9%

BRM

18.4%

CA Commercial Services

-4.3%

CA Market

Return vs Industry: BRM underperformed the Canadian Commercial Services industry which returned 19.9% over the past year.

Return vs Market: BRM exceeded the Canadian Market which returned -4.2% over the past year.


Shareholder returns

BRMIndustryMarket
7 Day0%-1.6%-1.0%
30 Day5.9%3.0%1.3%
90 Day12.5%6.3%1.9%
1 Year5.9%5.9%20.1%18.4%-0.9%-4.3%
3 Year-16.3%-16.3%53.1%43.4%6.4%-4.0%
5 Year-20.0%-20.0%105.7%83.9%33.3%12.8%

Price Volatility Vs. Market

How volatile is BIOREM's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BIOREM undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BRM (CA$0.36) is trading below our estimate of fair value (CA$1.07)

Significantly Below Fair Value: BRM is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BRM is unprofitable, so we can't compare its PE Ratio to the CA Commercial Services industry average.

PE vs Market: BRM is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BRM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BRM is good value based on its PB Ratio (1.1x) compared to the CA Commercial Services industry average (1.6x).


Next Steps

Future Growth

How is BIOREM forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

58.9%

Forecasted Commercial Services industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BIOREM has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BIOREM performed over the past 5 years?

10.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BRM is currently unprofitable.

Growing Profit Margin: BRM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BRM is unprofitable, but has reduced losses over the past 5 years at a rate of 10.3% per year.

Accelerating Growth: Unable to compare BRM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BRM is unprofitable, making it difficult to compare its past year earnings growth to the Commercial Services industry (15.4%).


Return on Equity

High ROE: BRM has a negative Return on Equity (-5.08%), as it is currently unprofitable.


Next Steps

Financial Health

How is BIOREM's financial position?


Financial Position Analysis

Short Term Liabilities: BRM's short term assets (CA$16.6M) exceed its short term liabilities (CA$6.9M).

Long Term Liabilities: BRM has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: BRM is debt free.

Reducing Debt: BRM has no debt compared to 5 years ago when its debt to equity ratio was 343.2%.

Debt Coverage: BRM has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BRM has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is BIOREM current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BRM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BRM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BRM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BRM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BRM's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average board tenure


CEO

Derek Webb

5.83yrs

Tenure

CA$244,250

Compensation

Mr. Derek S. Webb, P.Eng., MBA has been the Chief Executive Officer and President of BIOREM Inc. since December 17, 2014. Mr. Webb served as Executive Vice President of BIOREM Inc. from January 2012 to De ...


CEO Compensation Analysis

Compensation vs Market: Derek's total compensation ($USD185.99K) is about average for companies of similar size in the Canadian market ($USD171.43K).

Compensation vs Earnings: Derek's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Derek Webb
CEO, President & Director5.83yrsCA$244.25k0.77%
CA$ 110.8k
Brian Herner
Independent Director5.83yrsCA$28.45k0%
CA$ 0
Qingjie Zhao
Independent Chairman3.75yrsCA$35.25kno data
P. Ennis
Independent Director3.92yrsCA$28.45kno data
Ken Chen
Independent Director1.58yrsCA$25.95kno data
Vivian Yuan
Independent Director1.17yrsCA$4.21kno data

3.8yrs

Average Tenure

Experienced Board: BRM's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BIOREM Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BIOREM Inc.
  • Ticker: BRM
  • Exchange: TSXV
  • Founded:
  • Industry: Environmental and Facilities Services
  • Sector: Commercial Services
  • Market Cap: CA$14.305m
  • Shares outstanding: 38.66m
  • Website: https://www.biorem.biz

Location

  • BIOREM Inc.
  • 7496 Wellington Road 34
  • Guelph
  • Ontario
  • N1H 6H9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BRMTSXV (TSX Venture Exchange)YesCommon SharesCACADJan 2005
BIRM.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 2005

Biography

BIOREM Inc., an environmental biotechnology company, designs, manufactures, and sells air emissions control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air po ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 00:20
End of Day Share Price2020/10/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.